Compound Kushen Injection Inhibits Immune Evasion in Hepatocellular Carcinoma via PD-L1 O-GlcNAcylation
Compound Kushen Injection (CKI) inhibits glycolysis and immune evasion in HCC cells by reducing O-GlcNAcylation of PD-L1.
Phase III
Hepatocellular Carcinoma
Status
Active
Sponsor
PD-L1
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The findings regarding Compound Kushen Injection (CKI) present a significant opportunity for the oncology sector, particularly in enhancing treatment strategies for hepatocellular carcinoma (HCC). CKI's ability to inhibit immune evasion through modulation of PD-L1 O-GlcNAcylation suggests potential for novel combination therapies that could improve patient outcomes.
Recommended action
Humanexa recommends Investigate.
Analysis
Monitor further studies on CKI's clinical efficacy and ongoing trials targeting PD-L1 in HCC.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.